Village Farms International Third Quarter 2026 Earnings Call - VILLAGE FARMS INTERNATIONAL INC

Explicit Guidance:

• Revenue Growth: Expects stronger revenue growth in Q4 and throughout next year (FY2027) driven by the full planting of the Groningen facility and the ramp-up of Delta II capacity; no specific numerical revenue guidance provided for FY2027 or 2028.
• Capacity & Run Rates: Delta II expansion expected to reach full 40 metric ton annual run rate by the middle of next year (mid-2027); supports organic growth through 2028.
• Costs & Margins: Expect Q4 trim pricing and volumes to begin normalizing from Q3 lows (where spot trim pricing was down ~75% YoY) due to new contracted supply agreements; anticipate continued seasonality in Q4 with potential sequential revenue declines in European medical shipments.
• CapEx: No new formal CapEx guidance for future conversion of Delta I provided, noting a "cost-efficient plan" to mobilize Texas assets within 12 months.

Business-Segment Outlook:

• International (EU): Anticipates strong demand for EU GMP-compliant product outpacing current supply; pricing outlook remains favorable with no price reductions on compliant biomass; expects potential global shortages of compliant flour (estimated at 420 tons currently) if "greenwashing" (conversion of non-GMP flour) is curtailed by regulators.
• Canada: Aims for mid-single-digit market growth; committed to allocating majority of initial harvest from Delta II to domestic market to support share gains in vapes and infused pre-rolls; expects branded channel pricing to remain resilient (up 6% YoY in Q3) while non-branded volumes face headwinds from trim dynamics.
• Netherlands: Groningen facility fully planted; expects stronger revenue growth starting Q4 and into next year as propagation activities conclude; monitors Dutch regulatory monitoring reports which indicate positive consumer experience and potential for increased coffee shop permits.
• USA (Texas): Mobilizing plans to convert 30-acre, 1.3M sq ft Monahans greenhouse to cannabis production; expects facility to come online within a 12-month timeframe if regulatory pathways (e.g., TCUP program changes in Feb legislative session) permit; aims to leverage lowest US latitude for cost advantage (no supplemental lighting required).
• USA (Balanced Health Botanicals): Awaiting clarity on Dec 11 federal hemp ban and Medicaid/Medicare Innovation pilot outcomes; positioned to participate if non-synthetic full spectrum products are protected.
• Delta I Conversion: Expressed intent to exercise option to convert 25% of Delta I (700k sq ft) to cannabis production in 2027, providing capacity for an additional ~50-60 metric tons annually, contingent on demand and GMP certification readiness.

Market and Competitive Outlook:

• Supply/Demand Dynamics: Projects "reckoning" in next 1-2 years where operators lacking EU GMP certification or consistent volume capabilities will struggle; predicts market shift toward operators with "at-the-source" compliant capacity.
• Pricing: Expects trim pricing to normalize in Q4; confident EU GMP pricing will remain resilient due to regulatory tightening on conversion pathways in UK and Germany; believes competitors are de-emphasizing Canadian branded sales, creating room for Village Farms to gain share.
• Regulatory Impact: Anticipates that tightening UK/German requirements on "greenwashing" will create a supply shortage for compliant product, benefiting Village Farms' existing compliant inventory.
• Competitive Positioning: Claims to be the largest single-site EU GMP-certified facility globally; notes improving competitive dynamics in Canada as rivals exit dry flour or branded segments.

Macro / Industry Outlook:

• US Political Landscape: Highly optimistic post-midterm elections; cites incoming Congress as "most supportive of cannabis reform in American history"; expects federal rescheduling of adult cannabis to Schedule 3; predicts meaningful legislative changes in Texas (potentially full legalization) and other states (PA, IA, WI, KS).
• European Regulation: Regulatory winds in UK and Germany are shifting to favor source-certified GMP product over converted flour; expects government support for legal supply chains to replace illicit markets.
• Canadian Economy: Cannabis recognized as #5 cash crop nationally and #2 in BC; government moving to combat illicit market and implement a single federal excise stamp, expected to create operational efficiencies.
• Global Adoption: Believes the industry is in "very early innings" of global adoption with a long runway for value creation; anticipates advancement in botanical drug development and novel product commercialization.

Strategic Initiatives:

• Capacity Expansion: Delta II expansion on track for completion in Q1 (2027) to reach 40-ton run rate by mid-2027; Groningen facility ramp-up complete.
• Asset Activation: Planning to activate Texas Monahans facility within 12 months pending regulatory changes; exercising conversion rights for 25% of Delta I in 2027 (approx. 50-60 tons potential capacity).
• M&A Strategy: Will pursue "accretive" M&A opportunities that accelerate capabilities (e.g., route-to-market, IP) but remain disciplined on valuation; no immediate plans for "crazy" valued deals.
• Product Innovation: Shifting focus from pure cultivation to owning capabilities for product performance, distribution, and value creation; targeting broader cannabinoid applications and botanical drugs.
• Market Entry: Actively seeking entry into additional European markets once current capacity constraints are alleviated by Delta II expansion.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: US entry contingent on federal hemp ban outcome and Texas legislative session results; Netherlands legalization path uncertain (currently a 4-year experiment).
• Supply Constraints: Continued international growth is currently capped by supply limitations awaiting Delta II and Groningen full ramp-up.
• Price Volatility: Canadian spot trim market experienced severe compression (~75% drop YoY in Q3); potential for pricing pressure in Netherlands if coffee shop count continues to decline.
• Seasonality: Q4 typically sees declines in produce sales and European medical order volumes due to holiday timing and climate factors.
• Inventory/Working Capital: Future cash flows subject to variability from tax payments and inventory builds required for complex global supply chains.

Management Tone on the Future:

• Confidence: Highly confident and optimistic; describes the company as "uniquely positioned" to benefit from regulatory shifts and supply shortages.
• Strategic Shift: Tone indicates a move from "being defined by what we grow" to owning "capabilities that determine what is grown, how it performs, where it can be sold."
• Discipline: Emphasizes patience and discipline on M&A ("if a deal isn't strategically compelling... we simply won't do it") despite high confidence in organic growth and asset mobilization.
• Commitment: Reaffirmed commitment to the Canadian market despite short-term share struggles, citing long-term strategic value and competitive improvements.

Miscellaneous:

• Timeline Specifics: Texas facility conversion target: 12 months; Delta II full run rate: Mid-2027; Delta I conversion option exercise window: 2027; Texas legislative session expectations: Starting Feb.
• Capacity Math: Delta II (40 tons) + Delta I option (25% of facility) estimated at ~50-60 additional tons of annual capacity.
• Financial Position: Ended Q3 2026 with $80M cash, $41M net cash position, and $10M revolver undrawn; no dividends, buybacks, or specific tax rate guidance mentioned for future periods.